Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. (2018)
Attributed to:
Wellcome Trust MRC Cambridge Stem Cell Institute
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.2018.78.8414
PubMed Identifier: 30153096
Publication URI: http://europepmc.org/abstract/MED/30153096
Type: Journal Article/Review
Volume: 36
Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue: 34
ISSN: 0732-183X